Ophthotech Corp. has elected Adrienne Graves to be a board member, effective Dec. 12.
Graves is the former CEO of Santen Inc., the U.S. arm of Japan-based ophthalmic pharmaceutical company Santen Pharmaceutical Co. Ltd.
In addition, Michael Ross will step down as an independent board member at the end of February 2019.
New York-based Ophthotech is a biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases.